The Lancet Respiratory Medicine

Journal

Publication Venue For

  • Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.  10:888-899. 2022
  • The low flyers: persistent airflow limitation in young adults.  10:819-822. 2022
  • Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis.  10:289-297. 2022
  • Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.  9:1365-1376. 2021
  • Combination CFTR modulator therapy in children and adults with cystic fibrosis.  9:677-679. 2021
  • Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.  9:733-746. 2021
  • COPD exacerbations: finally, a more than ACCEPTable risk score.  8:939-941. 2020
  • Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  8:585-596. 2020
  • Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.  8:453-460. 2020
  • Exacerbations of chronic obstructive pulmonary disease: time to rename.  8:133-135. 2020
  • Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study.  8:34-44. 2020
  • The future of cystic fibrosis care: a global perspective.  8:65-124. 2020
  • Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial.  7:1039-1047. 2019
  • Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.  7:1027-1038. 2019
  • Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.  7:941-950. 2019
  • Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.  7:745-756. 2019
  • Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.  7:802-809. 2019
  • Eosinophil-guided treatment of COPD exacerbations: unfinished business.  7:647-648. 2019
  • Lung volume reduction for severe emphysema: good things come in small packages.  7:285-287. 2019
  • Ambulatory oxygen and quality of life in interstitial lung disease.  6:730-731. 2018
  • COPD ground zero: small airways rather than alveoli as the initial site of injury.  6:568-569. 2018
  • Deciphering COPD and associated cardiovascular impairment.  6:320-322. 2018
  • Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.  5:956-967. 2017
  • Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.  5:619-626. 2017
  • Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study.  5:627-638. 2017
  • Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.  5:500-511. 2017
  • Reappraisal of the clinical effect of mepolizumab – Authors' reply.  5:e21. 2017
  • Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.  5:390-400. 2017
  • A little CFTR can change a lot: slowing cystic fibrosis progression.  5:86-87. 2017
  • Cardiovascular disease in COPD: time to quash a silent killer.  4:687-689. 2016
  • Eosinophils in COPD: the Janus of phenotyping response to therapy?.  4:681-683. 2016
  • Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.  4:636-645. 2016
  • Meeting the challenge of COPD care delivery in the USA: A multiprovider perspective.  4:473-526. 2016
  • Pilot evaluation of ivacaftor for chronic bronchitis.  4:e32-e33. 2016
  • Serum eosinophils as a COPD biomarker: Ready for prime time?.  4:341-343. 2016
  • Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: An ancillary study to a randomised controlled trial.  4:203-212. 2016
  • Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study.  4:107-115. 2016
  • Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? - Authors' reply.  3:e27. 2015
  • Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial.  3:524-533. 2015
  • Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials.  3:435-442. 2015
  • Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: An observational study.  2:911-918. 2014
  • Cardiovascular disease in COPD: A call for action.  2:783-785. 2014
  • A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial.  2:527-538. 2014
  • Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial.  2:539-547. 2014
  • Risk loci for chronic obstructive pulmonary disease: A genome-wide association study and meta-analysis.  2:214-225. 2014
  • Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials.  1:210-223. 2013
  • GOLD 2011 disease severity classification in COPDGene: A prospective cohort study.  1:43-50. 2013
  • Author's reply.  1. 2013
  • International Standard Serial Number (issn)

  • 2213-2600
  • Electronic International Standard Serial Number (eissn)

  • 2213-2619